You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | -780.0% |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -4.0 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 0.0 | 21.4 |
Price / Book value | 1.2 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-03-31 | n/a | -3.12 | -2.70p | -7.1 | 0.0 | n/a | n/a | 0.0% |
2020-03-31 | n/a | -3.17 | -2.07p | -1.7 | 0.0 | n/a | n/a | 0.0% |
2021-03-31 | 0.19 | -3.21 | -1.82p | -4.1 | 0.0 | n/a | n/a | 0.0% |
2022-03-31 | n/a | -3.17 | -0.99p | -3.5 | 0.0 | n/a | n/a | 0.0% |
Evgen Pharma doses first volunteers in SFX-01 trial Sharecast News | 16 Nov |
---|---|
Evgen starts recruiting volunteers for trial of lead asset Sharecast News | 12 Oct |
Notice of Results | 26-May-23 19:28 |
---|---|
Preliminary results from Phase 1b study | 22-Mar-23 14:38 |
Price Monitoring Extension | 16-Mar-23 23:47 |
Second Price Monitoring Extn | 16-Mar-23 20:31 |
Price Monitoring Extension | 16-Mar-23 20:24 |